{"id":"W3046175925","doi":"10.1007/s40266-020-00783-w","title":"Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet","year":2020,"lang":"en","type":"article","venue":"Drugs & Aging","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Tolerability; Overactive bladder; Mirabegron; Medicine; Placebo; Urology; Pharmacotherapy; Double blind; Randomized controlled trial; Tolterodine; Double blind study; Pillar; Adverse effect; Internal medicine; Anesthesia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002682216,0.001469674,0.003196042,0.0005879272,0.0004681792,0.0009158995,0.0009060861,0.00163776,0.005553355],"category_scores_gemma":[0.002389559,0.000766227,0.001907411,0.0004038706,0.0009968124,0.001061206,0.0003524245,0.002579241,0.0008389801],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003104563,"about_ca_system_score_gemma":0.0008604163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003054459,"about_ca_topic_score_gemma":0.0006486786,"domain_scores_codex":[0.9989547,0.0006285896,0.00007328411,0.0001410728,0.000118153,0.00008427401],"domain_scores_gemma":[0.9986017,0.0003781606,0.0004740983,0.0001007021,0.0001140712,0.0003312253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9268374,0.02166463,0.001950941,0.002016074,0.002367811,0.000080089,0.0001412847,0.0003604007,0.01343399,0.0001198966,0.001235289,0.02979207],"study_design_scores_gemma":[0.8742515,0.1170655,0.0061175,0.00004845649,0.0006968255,0.00005425317,0.00002699527,0.0002291897,0.0005933071,0.00005406135,0.0008409501,0.00002149563],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803535,0.00787869,0.00140173,0.0005574579,0.0003083926,0.005645688,0.001936009,0.0002142958,0.001704202],"genre_scores_gemma":[0.9753886,0.005572546,0.004482677,0.001665756,0.0006008067,0.007230576,0.002103391,0.00005907595,0.002896626],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005553355,"threshold_uncertainty_score":0.01857787,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02976601168245524,"score_gpt":0.3183078597755697,"score_spread":0.2885418480931145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}